Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery Postmarket Registry
Launched by GLAUKOS CORPORATION · Apr 25, 2013
Trial Information
Current as of May 01, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Consecutive subjects in whom implantation of the iStent is attempted
- Exclusion Criteria:
- • Please refer to approved indications in Directions for Use
About Glaukos Corporation
Glaukos Corporation is a pioneering medical technology company dedicated to transforming the treatment of glaucoma and other eye diseases through innovative surgical and drug delivery solutions. With a strong focus on advancing patient care, Glaukos develops cutting-edge minimally invasive therapies that aim to reduce intraocular pressure and improve visual outcomes. Committed to rigorous clinical research and development, the company collaborates with healthcare professionals to bring forth effective and safe treatment options, enhancing the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Huntington Beach, California, United States
Durham, North Carolina, United States
Portland, Maine, United States
Fayetteville, North Carolina, United States
Santa Maria, California, United States
Ventura, California, United States
Quincy, Massachusetts, United States
Westwood, New Jersey, United States
Southern Pines, North Carolina, United States
Ladson, South Carolina, United States
Napa, California, United States
Parker, Colorado, United States
Bloomington, Minnesota, United States
Sioux Falls, South Dakota, United States
Chico, California, United States
Brecksville, Ohio, United States
Youngstown, Ohio, United States
Appleton, Wisconsin, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials